The availability of new drugs for hemophilia treatment.

Expert Review of Clinical Pharmacology
Massimo Morfini, Emanuela Marchesini

Abstract

A number of new FVIII/IX concentrates enriched the portfolio of products available for the treatment of hemophilia A/B patients. Due to the large inter-patient variability, accurate tailoring of the therapy became essential to improve patients' adherence, clinical outcomes, and cost/effectiveness ratio. Recently, non-replacement therapies have taken the limelight and succeeded in decreasing the bleedings of patients. The PK characteristics, efficacy, and safety of the new rFVIII and rFIX concentrates and of non-replacement therapy, are reported in detail in the published clinical trials. Outstanding improvements of rFIX concentrates' pharmacokinetics and pharmacodynamics have allowed to reduce the bleedings in hemophilia B patients, in order to increase their adherence to prophylaxis and quality of life. Less significant are the effects of pegylation or Fc fusion on the pharmacokinetics of the new rFVIII concentrates. The new non-replacement therapy is achieving the favor of many treaters and patients, in particular those with Factor VIII inhibitors. Great attention must be paid to the dangerous synergy of APCC and emicizumab, responsible for some fatal events during the clinical trials and compassionate use of this drug. So fa...Continue Reading

References

Feb 1, 1990·Acta paediatrica Scandinavica·R LjungI M Nilsson
Jul 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·E ErhardtsenO Nordfang
Mar 21, 1998·The Journal of Biological Chemistry·R J BaughS Krishnaswamy
Jun 3, 2000·Annual Review of Immunology·V Ghetie, E S Ward
Feb 5, 2003·The Journal of Experimental Medicine·Chaity ChaudhuryClark L Anderson
Jan 18, 2005·Trends in Cell Biology·Wayne I Lencer, Richard S Blumberg
Oct 8, 2005·American Journal of Physiology. Gastrointestinal and Liver Physiology·Jonghan KimClark L Anderson
Apr 12, 2006·Biochemistry·Chaity ChaudhuryClark L Anderson
May 24, 2006·Glycobiology·Shawn DeFreesHenrik Clausen
Aug 19, 2007·Nature Reviews. Immunology·Derry C Roopenian, Shreeram Akilesh
Nov 8, 2008·Thrombosis and Haemostasis·Henning R StennickeSøren E Bjørn
Nov 13, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·L ThimT D Steenstrup
Jan 9, 2010·Blood·Robert T PetersAlan J Bitonti
Jun 29, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·A Tagliaferri
Mar 29, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·L TangJ E Murphy
Nov 15, 2013·Blood·Johnny MahlanguUNKNOWN A-LONG Investigators
Dec 7, 2013·The New England Journal of Medicine·Jerry S PowellUNKNOWN B-LONG Investigators
Feb 27, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Henrik AgersøIda Hilden
Apr 26, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·K H HighD Lillicrap
May 21, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·U MartinowitzE Santagostino
Jun 4, 2015·Thrombosis Research·Stefan SchmidbauerStefan Schulte
Sep 16, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·A KlukowskaR Liesner
Nov 20, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·A TiedeM J Manco-Johnson

❮ Previous
Next ❯

Citations

Nov 17, 2021·Expert Opinion on Biological Therapy·Steven W PipeOscar G Segurado

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Expert Opinion on Emerging Drugs
Massimo Morfini, Ezio Zanon
The New England Journal of Medicine
P R Dallman, J G Pool
Indian Journal of Medical Sciences
M B Agarwal, B C Mehta
Expert Opinion on Drug Safety
Massimo Morfini, Carlo Antonio Paolo Rapisarda
Seminars in Thrombosis and Hemostasis
Massimo Franchini, Giuseppe Lippi
© 2022 Meta ULC. All rights reserved